Scientists use light to wake dormant cancer cells for treatment

AI Insight

Researchers have developed light-activated compounds that can selectively degrade glucocorticoid receptors in cancer cells, disrupting the stress hormone signaling that causes dormancy and drug resistance. The photoswitchable degraders allow targeted activation only in illuminated areas, potentially avoiding the systemic side effects that would occur from blocking these receptors throughout the body. This approach could wake dormant cancer cells in specific tumor sites, making them vulnerable to conventional treatments.

Why it matters

Dormant cancer cells are a major cause of treatment resistance and relapse, as they survive chemotherapy and later reactivate. This light-controlled method could enable doctors to selectively reactivate sleeping cancer cells in accessible tumors while preserving normal glucocorticoid receptor function in healthy tissues.